<The >Zilver? PTX? single arm study: 12-month results from the TASC C/D lesion subgroup

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3A00103157" target="_blank" >RIV/00843989:_____/13:00103157 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

<The >Zilver? PTX? single arm study: 12-month results from the TASC C/D lesion subgroup

Popis výsledku v původním jazyce

Aim. The aim of the present article was to report the 12-month results of the Zilver (R) PTX (R) Single Arm StudyTASC C/D de novo lesion subgroup. Methods. The Zilver PTX Drug-Eluting Peripheral Stent is a self-expanding nitinol stent with a polymer-freepaclitaxel coating. This is a prospective, single-arm, multicentre clinical study evaluating the Zilver PTX Drug-Eluting Peripheral Stent for treating patients with symptomatic lesions in the above-the-knee femoropopliteal artery. This study enrolled 787 patients (900 lesions) with Rutherford class 2 or higher treated with the Zilver PTX stent; 135 were long de novo lesions, corresponding to TASC II Class C or D. Results. The 135 long lesions had a mean length of 226.1 +/- 43.6 mm. The 12-month Kaplan-Meier estimates included a 77.6% primary patency rate, an 84.7% event-free survival rate, and an 85.4% rate of freedom from target lesion revascularization (TLR). The 12-month stent fracture rate was 2.1%. Conclusion. The primary patency

Název v anglickém jazyce

<The >Zilver? PTX? single arm study: 12-month results from the TASC C/D lesion subgroup

Popis výsledku anglicky

Aim. The aim of the present article was to report the 12-month results of the Zilver (R) PTX (R) Single Arm StudyTASC C/D de novo lesion subgroup. Methods. The Zilver PTX Drug-Eluting Peripheral Stent is a self-expanding nitinol stent with a polymer-freepaclitaxel coating. This is a prospective, single-arm, multicentre clinical study evaluating the Zilver PTX Drug-Eluting Peripheral Stent for treating patients with symptomatic lesions in the above-the-knee femoropopliteal artery. This study enrolled 787 patients (900 lesions) with Rutherford class 2 or higher treated with the Zilver PTX stent; 135 were long de novo lesions, corresponding to TASC II Class C or D. Results. The 135 long lesions had a mean length of 226.1 +/- 43.6 mm. The 12-month Kaplan-Meier estimates included a 77.6% primary patency rate, an 84.7% event-free survival rate, and an 85.4% rate of freedom from target lesion revascularization (TLR). The 12-month stent fracture rate was 2.1%. Conclusion. The primary patency

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of cardiovascular surgery

ISSN

0021-9509

e-ISSN

—

Svazek periodika

54

Číslo periodika v rámci svazku

n. 1

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

8

Strana od-do

"p. 115-122"

Kód UT WoS článku

000316504500013

EID výsledku v databázi Scopus

—